South Africa Biopharmaceuticals Market - Industry Outlook & Forecast 2023-2028

South Africa Biopharmaceuticals Market - Industry Outlook & Forecast 2023-2028


The South Africa biopharmaceuticals market is expected to grow at a CAGR of 12.30% from 2022 to 2028.

MARKET TRENDS AND DRIVERS

Promising Signs for Local Biopharmaceutical Production in South Africa

The promising signs for local biopharmaceutical production in South Africa reflect a growing interest in developing a robust and self-sufficient pharmaceutical industry. With strong government support, research advancements, collaborative partnerships, and a focus on addressing healthcare demands, the country is poised to make significant strides in biopharmaceuticals. By fostering local production, the South Africa biopharmaceuticals market can improve access to essential medicines, drive healthcare innovation, and contribute to economic development, ultimately benefiting the healthcare sector and the well-being of its population.

Growing Pharmaceutical Industry & Investment Opportunities

The growing South Africa biopharmaceuticals market presents ample investment opportunities for companies and investors. The country's expanding market size, disease burden, government support, local manufacturing focus, robust regulatory environment, and potential for regional market access contribute to its attractiveness as a pharmaceutical investment destination. As the healthcare landscape continues to evolve, companies investing in research, development, and manufacturing capabilities are well-positioned to capitalize on the country's burgeoning pharmaceutical market and improve healthcare outcomes for the South African population and beyond.

Growing Access to CGTs in South Africa

The growing access to cell and gene therapies in South Africa presents a transformative opportunity to revolutionize healthcare and improve patient outcomes. With the potential to address genetic and rare diseases, enhance cancer care, and offer personalized medicine, these therapies are poised to impact healthcare delivery profoundly. As the South Africa biopharmaceuticals market embraces these innovations and establishes supportive policies and infrastructure, the region can position itself at the forefront of biomedical research and become a hub for cutting-edge therapies, unlocking new possibilities for patients and healthcare providers.

Increasing Prevalence of Chronic Diseases & Growing Aging Population

The increasing prevalence of chronic diseases and the growing aging population in South Africa are compelling factors that necessitate a proactive and comprehensive approach to healthcare. Addressing these challenges requires strategic planning, increased investment in healthcare infrastructure, preventive health initiatives, and equitable access to healthcare services. By focusing on these areas, South Africa can improve health outcomes, enhance the quality of life for its citizens, and build a more resilient and sustainable healthcare system to meet future needs.

Increasing Focus on Precision Medicine

The increasing focus on precision medicine in South Africa marks a transformative shift in healthcare, offering the potential to revolutionize patient care and disease management. By leveraging genomic data, health informatics, and targeted therapies, precision medicine aims to deliver more effective, personalized, and patient-centric healthcare solutions. As the region continues to advance its precision medicine capabilities, integrating genomic insights into clinical practice holds the promise of improving health outcomes, reducing healthcare costs, and enhancing the quality of life for the population.

SEGMENTATION INSIGHTS

INSIGHTS BY PRODUCT

The South Africa biopharmaceuticals market by product segments as vaccines, monoclonal antibodies, recombinant proteins & hormones, and tissue, cell & gene therapies. The vaccines segment accounted for the largest segmental share. Vaccines are pivotal in public health, preventing and controlling infectious diseases that threaten communities worldwide. In South Africa, vaccines are a cornerstone of the biopharmaceuticals market, providing essential protection against various infectious diseases and contributing to the nation's efforts to improve public health and healthcare outcomes. Government initiatives and partnerships with international organizations have been instrumental in driving vaccine development and distribution in South Africa. The country’s government, WHO, and other global health entities have implemented immunization programs targeting various age groups and high-risk populations.

Segmentation by Product
  • Vaccines
  • Monoclonal Antibodies
  • Recombinant Proteins & Hormones
  • Tissue, Cell & Gene Therapies
INSIGHTS BY THERAPY AREA

The infectious diseases by therapy area segment accounted for the largest South Africa biopharmaceuticals market share. Infectious diseases have long been a significant public health concern in South Africa, posing challenges to the healthcare system and population. The country's biopharmaceutical market is crucial in addressing these challenges by providing innovative and effective treatments and preventive measures against infectious diseases. The biopharmaceuticals market in the region has played a pivotal role in addressing infectious diseases through developing and distributing vaccines, antiviral drugs, antibiotics, and other therapeutics. Antiretroviral therapy (ART) has been a game-changer in managing HIV/AIDS, improving HIV-positive individuals' quality of life and life expectancy.

Segmentation by Therapy Area
  • Infectious Diseases
  • Diabetes
  • Oncology
  • Inflammation & Immunology
  • Other Therapy Areas
VENDOR LANDSCAPE

The South Africa biopharmaceuticals market is a dynamic and rapidly growing sector, driven by increasing healthcare needs, a rising burden of chronic diseases, and advancements in medical research and biotechnology. The industry is characterized by intense competition among pharmaceutical companies vying for a share in this lucrative and critical industry.

Key Company Profiles
  • AbbVie
  • F. Hoffmann-la Roche
  • GSK
  • Johnson & Johnson
  • Merck & Co.
  • Novartis
  • Novo Nordisk
  • Pfizer
  • Sanofi
Other Prominent Vendors
  • Amgen
  • Biocon
  • Biogen
  • Cipla
  • Eli Lilly and Company
  • Teva Pharmaceutical Industries
  • Viatris
KEY QUESTIONS ANSWERED:

1. How big is the South African biopharmaceuticals market?

2. What is the South Africa biopharmaceuticals market's projected growth rate?

3. Who are the key players in the South Africa biopharmaceuticals market?

4. What are the rising trends in the South African biopharmaceuticals market?

5. Which therapy area holds the most significant South African biopharmaceuticals market share?


1 RESEARCH METHODOLOGY
2 RESEARCH OBJECTIVES
3 RESEARCH PROCESS
4 SCOPE & COVERAGE
4.1 MARKET DEFINITION
4.1.1 INCLUSIONS
4.1.2 EXCLUSIONS
4.1.3 MARKET ESTIMATION CAVEATS
4.2 BASE YEAR
4.3 SCOPE OF THE STUDY
4.3.1 MARKET SEGMENTATION BY PRODUCT
4.3.2 MARKET SEGMENTATION BY THERAPY AREA
4.3.3 MARKET SEGMENTATION BY GEOGRAPHY
5 REPORT ASSUMPTIONS & CAVEATS
5.1 KEY CAVEATS
5.2 CURRENCY CONVERSION
5.3 MARKET DERIVATION
6 MARKET AT A GLANCE
7 PREMIUM INSIGHTS
7.1 OVERVIEW
7.1.1 PRODUCT SEGMENTATION INSIGHTS
7.1.2 THERAPY AREA SEGMENTATION INSIGHTS
8 INTRODUCTION
8.1 BIOPHARMACEUTICALS: OVERVIEW
8.1.1 GLOBAL BIOPHARMACEUTICALS MARKET SCENARIO
8.1.2 SOUTH AFRICA BIOPHARMACEUTICALS MARKET SCENARIO
8.2 BIOPHARMA MANUFACTURING
8.2.1 ADVANCES IN BIOPHARMA MANUFACTURING
8.2.2 IMPORTANCE OF SINGLE-USE BIOPROCESSING IN BIOLOGICS MANUFACTURING
8.3 REGULATORY SCENARIO OF BIOPHARMACEUTICALS IN SOUTH AFRICA
8.4 REIMBURSEMENT SCENARIO OF BIOPHARMACEUTICALS IN SOUTH AFRICA
8.5 SUPPLY CHAIN OF BIOPHARMACEUTICALS
8.6 COVID-19 IMPACT ANALYSIS
8.6.1 POSSIBLE IMPACT OF THE COVID-19 PANDEMIC ON THE BIOPHARMACEUTICALS MARKET
8.6.2 PRE-COVID & POST-COVID MARKET SCENARIO OF BIOPHARMACEUTICALS
9 MARKET OPPORTUNITIES & TRENDS
9.1 PROMISING SIGNS FOR LOCAL BIOPHARMACEUTICAL PRODUCTION IN SOUTH AFRICA
9.2 INCREASED ADOPTION OF BIOSIMILARS
9.3 GROWTH OF PHARMACEUTICAL INDUSTRY & INVESTMENT OPPORTUNITIES
9.4 INCREASED ACCESS TO CGT IN SOUTH AFRICA
10 MARKET GROWTH ENABLERS
10.1 PREVALENCE OF CHRONIC DISEASES & LARGE AGING POPULATION
10.1.1 TOP CHRONIC DISEASES IN SOUTH AFRICA
10.2 INCREASED FOCUS ON PRECISION MEDICINE
10.3 BIOLOGICS UPTAKE & POTENTIAL IN SOUTH AFRICA
11 MARKET RESTRAINTS
11.1 LACK OF MANUFACTURING CAPABILITIES
11.2 HIGH DEVELOPMENT COST OF BIOLOGICS
11.3 POOR PATIENT ACCEPTANCE & ACCESS TO BIOLOGICS
12 MARKET LANDSCAPE
12.1 MARKET OVERVIEW
12.2 MARKET SIZE & FORECAST
12.3 MARKET OPPORTUNITY
12.3.1 MARKET OPPORTUNITY BY PRODUCT
12.3.2 MARKET OPPORTUNITY BY THERAPY AREA
12.4 FIVE FORCES ANALYSIS
12.4.1 THREAT OF NEW ENTRANTS
12.4.2 BARGAINING POWER OF SUPPLIERS
12.4.3 BARGAINING POWER OF BUYERS
12.4.4 THREAT OF SUBSTITUTES
12.4.5 COMPETITIVE RIVALRY
13 PRODUCT
13.1 MARKET SNAPSHOT & GROWTH ENGINE
13.2 MARKET OVERVIEW
13.3 VACCINES
13.3.1 MARKET OVERVIEW
13.3.2 MARKET SIZE & FORECAST
13.4 MONOCLONAL ANTIBODIES
13.4.1 MARKET OVERVIEW
13.4.2 MARKET SIZE & FORECAST
13.5 RECOMBINANT PROTEINS & HORMONES
13.5.1 MARKET OVERVIEW
13.5.2 MARKET SIZE & FORECAST
13.6 TISSUE, CELL & GENE THERAPIES
13.6.1 MARKET OVERVIEW
13.6.2 MARKET SIZE & FORECAST
14 THERAPY AREA
14.1 MARKET SNAPSHOT & GROWTH ENGINE
14.2 MARKET OVERVIEW
14.3 INFECTIOUS DISEASES
14.3.1 MARKET OVERVIEW
14.3.2 MARKET SIZE & FORECAST
14.4 DIABETES
14.4.1 MARKET OVERVIEW
14.4.2 MARKET SIZE & FORECAST
14.5 ONCOLOGY
14.5.1 MARKET OVERVIEW
14.5.2 MARKET SIZE & FORECAST
14.6 INFLAMMATION & IMMUNOLOGY
14.6.1 MARKET OVERVIEW
14.6.2 MARKET SIZE & FORECAST
14.7 OTHER THERAPY ARAES
14.7.1 MARKET OVERVIEW
14.7.2 MARKET SIZE & FORECAST
15 COMPETITIVE LANDSCAPE
15.1 COMPETITION OVERVIEW
15.1.1 KEY HIGHLIGHTS OF SOUTH AFRICA BIOPHARMACEUTICALS MARKET
15.2 MARKET SHARE ANALYSIS
15.2.1 ABBVIE
15.2.2 F. HOFFMANN-LA ROCHE
15.2.3 GSK
15.2.4 JOHNSON & JOHNSON
15.2.5 MERCK & CO.
15.2.6 NOVARTIS
15.2.7 NOVO NORDISK
15.2.8 PFIZER
15.2.9 SANOFI
16 KEY COMPANY PROFILES
16.1 ABBVIE
16.1.1 BUSINESS OVERVIEW
16.1.2 PRODUCT OFFERINGS
16.1.3 KEY STRATEGIES
16.1.4 KEY STRENGTHS
16.1.5 KEY OPPORTUNITIES
16.2 F. HOFFMANN-LA ROCHE
16.2.1 BUSINESS OVERVIEW
16.2.2 PRODUCT OFFERINGS
16.2.3 KEY STRATEGIES
16.2.4 KEY STRENGTHS
16.2.5 KEY OPPORTUNITIES
16.3 GSK
16.3.1 BUSINESS OVERVIEW
16.3.2 PRODUCT OFFERINGS
16.3.3 KEY STRATEGIES
16.3.4 KEY STRENGTHS
16.3.5 KEY OPPORTUNITIES
16.4 JOHNSON & JOHNSON
16.4.1 BUSINESS OVERVIEW
16.4.2 PRODUCT OFFERINGS
16.4.3 KEY STRATEGIES
16.4.4 KEY STRENGTHS
16.4.5 KEY OPPORTUNITIES
16.5 MERCK & CO.
16.5.1 BUSINESS OVERVIEW
16.5.2 PRODUCT OFFERINGS
16.5.3 KEY STRATEGIES
16.5.4 KEY STRENGTHS
16.5.5 KEY OPPORTUNITIES
16.6 NOVARTIS
16.6.1 BUSINESS OVERVIEW
16.6.2 PRODUCT OFFERINGS
16.6.3 KEY STRATEGIES
16.6.4 KEY STRENGTHS
16.6.5 KEY OPPORTUNITIES
16.7 NOVO NORDISK
16.7.1 BUSINESS OVERVIEW
16.7.2 PRODUCT OFFERINGS
16.7.3 KEY STRATEGIES
16.7.4 KEY STRENGTHS
16.7.5 KEY OPPORTUNITIES
16.8 PFIZER
16.8.1 BUSINESS OVERVIEW
16.8.2 PRODUCT OFFERINGS
16.8.3 KEY STRATEGIES
16.8.4 KEY STRENGTHS
16.8.5 KEY OPPORTUNITIES
16.9 SANOFI
16.9.1 BUSINESS OVERVIEW
16.9.2 PRODUCT OFFERINGS
16.9.3 KEY STRATEGIES
16.9.4 KEY STRENGTHS
16.9.5 KEY OPPORTUNITIES
17 OTHER PROMINENT VENDORS
17.1 AMGEN
17.1.1 BUSINESS OVERVIEW
17.1.2 PRODUCT OFFERINGS
17.2 BIOCON
17.2.1 BUSINESS OVERVIEW
17.2.2 PRODUCT OFFERINGS
17.3 BIOGEN
17.3.1 BUSINESS OVERVIEW
17.3.2 PRODUCT OFFERINGS
17.4 CIPLA
17.4.1 BUSINESS OVERVIEW
17.4.2 PRODUCT OFFERINGS
17.5 ELI LILLY AND COMPANY
17.5.1 BUSINESS OVERVIEW
17.5.2 PRODUCT OFFERINGS
17.6 TEVA PHARMACEUTICAL INDUSTRIES
17.6.1 BUSINESS OVERVIEW
17.6.2 PRODUCT OFFERINGS
17.7 VIATRIS
17.7.1 BUSINESS OVERVIEW
17.7.2 PRODUCT OFFERINGS
18 REPORT SUMMARY
18.1 KEY TAKEAWAYS
18.2 STRATEGIC RECOMMENDATIONS
19 QUANTITATIVE SUMMARY
19.1 MARKET BY PRODUCT
19.2 MARKET BY THERAPY AREA
20 APPENDIX
20.1 ABBREVIATIONS

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings